XML 80 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
16. Segment Information
3 Months Ended 12 Months Ended
Mar. 31, 2014
Dec. 31, 2013
Segment Information    
NOTE 16 - Segment Information

In 2013, ProElite was considered to be an operating segment pursuant to ASC Topic 280 “Segment Reporting” since each was budgeted separately and tracked separately to provide the chief operating decision maker information to assess and manage ProElite, Stratus White and Hygeia/Canterbury. The Company suspended operations of ProElite effective June 30, 2013. Following the repositioning of the Company as a specialty biopharmaceutical company, the Company’s Board of Directors voted to discontinue operations of ProElite effective March 31, 2014. The following segment information is presented to provide a comparison for the three months ended March 31, 2014 and 2013.

   

A summary of results by segments is as follows:

 

   Three Months Ended March 31, 2014 ($000)   Three Months Ended March 31, 2013 ($000) 
   Bio-   ProElite           Bio-   ProElite         
   Pharma   (Discont.)   Other   Total   Pharma   (Discont.)   Other   Total 
Revenues  $   $   $   $   $   $   $   $ 
Cost of sales                                
Gross margin                                
Deprec. & Amort   1        477    478            9    9 
Segment profit   (1)       (477)   (478)           (9)   (9)
Operating expenses   183        710    893            2,084    2,084 
Other (income)/expenses           5    5            20    20 
Impact of derivative securities                           237    237 
Net loss from continuing ops.   (184)       (1,192)   (1,376)           (2,350)   (2,350)
Loss from discontinued ops.                       (127)       (127)
Preferred dividends                           124    124 
Net loss attributable to common shareholders  $(184)  $   $(1,192)  $(1,376)  $   $(127)  $(2,474)  $(2,601)
                                         
Assets at End of Period  $230   $344   $25,878   $26,452   $   $1,677   $511   $2,188 
Liabilities at End of Period  $2,779   $625   $7,291   $10,695   $   $1,998   $19,927   $21,925 

 

In 2013, ProElite, Stratus White and Hygeia/Canterbury were considered operating segments pursuant to ASC Topic 280 “Segment Reporting” since each was budgeted separately and tracked separately to provide the chief operating decision maker information to assess and manage ProElite, Stratus White and Hygeia/Canterbury. In 2012, ProElite and Stratus White were considered operating segments. In 2012, the Company decided to suspend development of all business activities other than ProElite and effective June 30, 2013, the Company decided to suspend development of its ProElite business.

  

A summary of results by segments is as follows:

 

   As of/for the Year Ended December 31, 2013   As of /for the Year Ended December 31, 2012 
   Stratus Rewards     ProElite    Life Sciences    Other     Total    Stratus Rewards     ProElite    Other Events     Other     Total  
Revenues  $   $72   $   $   $72   $   $375   $   $   $375 
Cost of sales                           236            236 
Gross margin       72            72        139          139
Deprec. & Amort       2    87    587    676        2        32    34 
Segment profit       70    (87)   (587)   (604)      137      (32)   105
Operating expenses   85    192    80    12,371    12,728   1,724    990        9,183    11,897 
Other (income) expenses       (714)       643    (71)       97        1,763   1,859
Impact of derivative securities               (10,459)   (10,459)                  (6,801)   (6,801)
Net loss  $(85)  $592  $(167)  $(3,142)   (2,802)  $(1,724)  $(950)  $  $(4,177)  $(6,850)
Net loss attributable to non-controlling interests               (6)   (6)                (19)    (19)
Preferred dividend               (172)   (172)               497    497 
Net loss attributable to common shareholders  $(85)  $592   $(167)  $(2,976)  $(2,636)  $(1,724)  $(950)  $   $(4,693)  $(7,366)
                                                   
Assets  $   $230   $572   $17,542   $18,344   $   $2,161   $   $285   $2,446 
Liabilities  $52   $2,779   $587   $5,460   $8,878   $122   $2,632   $2,271   $15,828   $20,853